News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Allos Therapeutics` CEO Stephen Hoffman talks to The Wall Street Transcript (Business Wire) ...By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy.......Allos is currently conducting a pivotal Phase III trial for the treatment of metastatic brain tumors.... - Oct 03 11:28 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/011003/30374_1.html

Posted on: 10/03/2001

"Yahoo - Allos Therapeutics' CEO Stephen Hoffman talks to The Wall Street Transcript"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ALTH
4.61
-0.24
delayed 20 mins - disclaimer

Wednesday October 3, 11:28 am Eastern Time

Press Release

SOURCE: Allos Therapeutics, Inc.

Allos Therapeutics' CEO Stephen Hoffman talks to The Wall Street Transcript

NEW YORK--(BUSINESS WIRE)--Oct. 3, 2001--The Wall Street Transcript has published an in-depth interview with Dr. Stephen Hoffman, CEO of Allos Therapeutics (Nasdaq:ALTH - news), in which he talks at length about the company's future.

The entire 2,000-word interview is available free online at http://www.twst.com/ceos.htm

Hoffman gives an overview of the company. "Allos Therapeutics has been in operation since 1994. We are focused on developing a new class of pharmaceutical compounds described as synthetic allosteric modifiers. The first product we have in clinical development from this new class of agents is designated RSR13. RSR13 has a unique mechanism of action that increases the release of oxygen from hemoglobin, the oxygen carrying protein contained within red blood cells. By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy. Allos is currently conducting a pivotal Phase III trial for the treatment of metastatic brain tumors. We expect to complete enrollment in this pivotal, Phase III clinical trial in approximately 12-15 months."

Hoffman explains, Allos is the only company developing a drug that increases the amount of oxygen in the tumor to increase the effectiveness of therapy. Oxygen is a required component of radiation therapy -- without sufficient levels in the tumor, radiation isn't effective. There are a couple of other companies developing radiation sensitizers that have less clear mechanisms of action."

Looking forward, Hoffman states, "By 2005, we would certainly hope to have RSR13 on the market as a radiation sensitizing agent in North America and on the market in Europe for our lead treatment indication of treating metastatic brain tumors. Also by that time, we would have completed a number of label expansion studies showing proof of principle for the effectiveness of RSR13 in treating other types of malignant tumors, for example, in the treatment of primary lung cancer, primary brain cancer, cervical cancer and other tumors that collectively result in 750,000 patients receiving radiation therapy per year in the US alone."

This interview is part of a 179-page Biotechnology Issue available at http://www.twst.com/info/info423.htm or by calling 212/952-7433

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.


Contact:
     Allos Therapeutics, Inc.
     Monique Greer, 303/426-6262

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Allos Therapeutics Inc (NasdaqNM:ALTH - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database or redistribution in a computer network is strictly forbidden.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740